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S u m m a r y
This is a current review on the circulating tumour cells (CTC) in patients with renal cell carcinoma as a potential diagnostic 
tool that will allow for more accurate assessment of advanced disease and the monitoring of treatment effects. Using current 
diagnostic methods, we are still unable to identify patients especially prone to metastases. Assaying for levels of CTC may 
become a useful diagnostic tool, which will help to assess disease stage with more accuracy as well as monitor treatment 
outcomes. The introduction of “liquid biopsy”, for screening and treatment monitoring, forms a very attractive outlook, where 
cases could be easily found by a blood test.
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S t r e s z c z e n i e
Opracowanie zawiera współczesne poglądy na temat oznaczania liczby krążących we krwi komórek nowotworowych 
(CTC) u chorych na raka nerkowokomórkowego, jako potencjalnego narzędzia diagnostycznego, które pozwoli na dokład-
niejszą ocenę stopnia zawansowania choroby i monitorowania efektów leczenia. Stosując obecne metody diagnostyczne nie 
potrafimy wyodrębnić grupy pacjentów szczególnie narażonych na wystąpienie przerzutów. Oznaczanie liczby krążących we 
krwi pacjentów CTC może stać przydatnym narzędziem diagnostycznym, które pozwoli na dokładniejszą ocenę stopnia za-
wansowanie choroby i monitorowanie efektów leczenia. Bardzo kusząca jest wizja wprowadzenia do diagnostyki przesiewo-
wej i oceny skuteczności leczenia Liquid biopsy, która pozwala na szybkie wykrycie nowotworu na podstawie badania krwi.
Słowa kluczowe: komórki nowotworowe, guzy lite, układ moczowo-płciowy
INTrODUCTION
Circulating Tumour Cells (CTC) are a population of 
cells that have detached from the tumour mass and are 
able to disseminate via the vascular system and cre-
ate metastatic foci in the body (1). Initially, the immune 
system eliminates the circulating cancer cells from the 
bloodstream, but over time, the cells remain there for 
longer periods and become identifiable. The first pub-
lished report of circulating tumour cells dates back to 
1869 (2).
Prospective studies have demonstrated the ef-
fectiveness of identifying and quantifying CTCs in 
the prediction of malignant tumour treatment out-
comes, including cancers of the breast, colon and 
prostate (3). Currently, intensive research is conduct-
ed on the importance of CTC in the biology and ther-
apy of renal cell carcinoma (rCC) and transitional cell 
carcinoma (TCC). CTCs can be isolated from patients’ 
blood in the course of most cancers due to the ease of 
identification of the epithelial phenotype of the cancer. 
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The presence of such cells in the blood coexists with 
micrometastases, which are clinically silent, and/or pre-
cedes the clinical emergence of metastases (4). CTCs 
are suspected of being instrumental for dissemination 
of the cancer during surgery, which involves mechani-
cal manipulation and traumatisation of the primary tu-
mour (5).
The circulating cells acquire properties of mesechy-
mal cells, i.e. they are able to function independently. 
This is known as Epithelial to Mesenchymal Transition 
(EMT) (6). As a result of changes in their adhesion mol-
ecules, the cells separate from the primary cell popula-
tion and gain the ability to migrate independently within 
the extracellular matrix and, eventually, outside it (7). 
The reverse process, known as Mesenchymal to Epi-
thelial Transition (MET), is one of the most important 
stages of the development of cancer metastases. Arm-
strong et al. demonstrated that 80% of circulating cells 
of prostate or breast cancer express mesenchymal and 
epithelial markers (8). The authors suggested that the 
ratio of these markers could be a valuable prognostic 
parameter.
Circulating cancer cells are gradually gaining im-
portance in clinical medicine. Many studies have espe-
cially been published on the subject of prostate cancer, 
where authors underscore the potential role of CTC in 
the prediction of survival and treatment outcomes. The 
presence of CTC in the patient’s bloodstream is consis-
tent with disease that is refractory to a given treatment, 
which therefore requires modification (9). It has been 
demonstrated in an animal model that approximately 
10 CT cells are sufficient to develop a new tumour in 
the case of renal or prostate cancer (10). Identifying 
CTC may in future help to discern patients who, ac-
cording to standard diagnostic methods, are not quali-
fied to undergo further radical treatment due to unfa-
vourable prognosis regarding cure (11).
The isolation and identification of CTC is a chal-
lenge for the biotechnological industry. The main issue 
remains the small number of cells available for study. 
Normally, blood is drawn in samples of 5 to 10 ml. In a 
majority of cancers, the available methods are able 
to identify no less than 10 CTC in 1 ml of blood (12). 
These data regard cut-off thresholds, hence they cast 
doubt on experimentally applied norms. Moreover, cur-
rent diagnostic methods do not allow for identification 
of CTCs in frozen or preserved blood. This excludes 
potential retrospective studies, which would certainly 
accelerate the wide introduction of CTC-based assays 
into clinical practice.
CellSearch is currently the only system with FDA 
(Food and Drug Administration, USA) approval for use 
in determining the number of circulating cancer cells 
(13). Nonetheless, many new devices for isolating CTC 
have been presented. Clinical trials are under way to 
assess the effectiveness of electric biosensors used to 
rapidly identify CTC in a small volume of blood (14,15). 
Progress in the isolation and identification of CTC, as 
well as the understanding of the value of CTC in the 
prevention and treatment of solid tumours, may in fu-
ture allow for a “liquid biopsy”, which would identify 
CTC in the patient’s blood sample and help to plan in-
dividualised treatment (16).
PrOSTATE CANCEr
The number of identified CTC in prostate cancer pa-
tients may in the near future become a valuable pa-
rameter used to assess the disease stage and improve 
treatment outcomes. In a clinical study, Stott et al. dem-
onstrated that on average approximately 100 CTCs 
were found in patients with prostate cancer. The num-
ber of CTC fell in all patients on the first day following 
radical prostatectomy (17).
In prostate cancer patients, the number of CTC 
correlates with the PSA level (18). Twenty per cent 
of patients with an elevated PSA in the range of 2.5 to 
10 ng/ml were found to have CTC in peripheral blood 
(19). The same study revealed that CTC were present 
in 21% of patients who had undergone radical pros-
tatectomy. Moreno et al. demonstrated that the pres-
ence of at least 5 CTC in 7.5 ml of peripheral blood in 
patients with metastatic prostate cancer correlates with 
poor survival (20). Twenty three patients of 37 had more 
than 5 CTC. Similar results were obtained by Okegawa 
et al., who showed that the finding of at least 5 CTC in 
patients with a hormone-refractory prostate cancer is 
associated with reduced survival (21).
In a large group of patients with prostate cancer, 
Olmos et al. showed that the reduction of CTC below 
5, following chemotherapy, correlates with longer sur-
vival compared to a reduction of CTC to a value above 
5 cells (22). Besides survival prediction, CTC can help 
qualify patients to undergo appropriate treatments. 
Goldman et al. found that the number of CTC reflected 
the tumour’s hormone sensitivity and also helped to as-
sess the risk of the emergence of hormone resistance 
(23). Ogegawa et al. determined a higher susceptibility 
of the prostate cancer to induced hypogonadism in pa-
tients who were found to have over 5 circulating pros-
tate cancer cells (24).
rENAL CANCEr
In 2009, 3650 cases of renal cancer were diagnosed 
in Poland. According to predictions, the incidence of 
this tumour will grow by an annual rate of about 2.5% 
(1, 25).
The universal availability of imaging studies serves 
to significantly increase the fortuitous identification of 
malignant renal tumours in various stages. It is char-
acteristic for renal cancer to frequently generate local 
relapses and distant metastases, which are found even 
years following primary surgical treatment. Patients 
with this tumour require prolonged follow up, which 
should exceed 5 years after surgery (26).
CTC can be found in patients with renal cell carci-
noma. The identification of CTC in the patients’ blood-
stream precedes the emergence of clinically identifi-
able lesions. The circulating renal carcinoma cells are 
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characterised by the presence of cytokeratins 8, 18, 19 
and surface glycoprotein CD 44 (27). Not many pub-
lished clinical studies have addressed correlations be-
tween the number of CTC in the patients’ blood and 
their prognosis or treatment outcomes. Bluemke et al. 
are the only authors to have shown a correlation be-
tween the presence of CTC in renal cancer and the 
disease stage or the risk of metastases (28).
TrANSITIONAL CELL CArCINOMA OF THE BLADDEr
In Poland, transitional cell carcinoma of the blad-
der has the fourth highest incidence among cancers 
in men and the eighth in women. The majority of cases 
are non-invasive tumours, of which 75% develop mul-
tiple relapses following sparing surgical treatment (29). 
According to estimates, over 50% of patients with non-
invasive cancers will sustain a disease progression to 
N1 within 2 years. This is a consequence of the unavail-
ability of an easily accessible method of identifying ma-
lignant infiltration that exceeds the bladder epithelium 
and threatens with dissemination of cancer cells in the 
vascular system (30). The detection of CTC in a patient’s 
bloodstream may effectively supplement current man-
agement and disease progression monitoring. CTC are 
present in patients with urothelial cancer. Naoe et al. 
were among the first to publish results of assaying 
for CTC levels in patients with this tumour. In their 
study, they found a significant difference in CTC 
levels between patients with non-invasive vs. inva-
sive and metastasising cancer (31). This is a valuable 
observation, which may broaden the portfolio of avail-
able diagnostic parameters used to stage the disease 
and select methods and duration of treatment. rink et 
al. assessed the prognostic value of CTC identification 
in a larger group of patients with invasive, non-meta-
static bladder cancer (T3, N0) and demonstrated that 
the number of CTC correlates with survival following 
surgery. Out of the 50 subjects, 15 were found to have 
approx. 33 CTC in 7.5 ml of blood. The majority of CTC-
positive subjects died within a year from implementa-
tion of radical surgical treatment (32). The number of 
CTC precisely reflects the number of metastases found 
in PET and MrI studies (33). The study by Okegawa 
et al. found CTC in all patients with TCC in stages N1 
and N2. On the other hand, no CTC were found in the 
bloodstream of any of the subjects with a stage N0 tu-
mour (34). While these results are promising, data are 
still lacking to determine a cut-off level below which the 
number of CTC could be deemed “safe” (35). Studies 
are also needed to assess the levels of CTC in patients 
with non-advanced bladder cancer
SUMMAry
Using current diagnostic methods, we are still un-
able to identify patients especially prone to metasta-
ses. Assaying for levels of CTC may become a useful 
diagnostic tool, which will help to assess disease stage 
with more accuracy as well as monitor treatment out-
comes. The introduction of “liquid biopsy”, for screen-
ing and treatment monitoring, forms a very attractive 
outlook, where cases could be easily found by a blood 
test. The CTC are among the major markers applied in 
clinical trials of “liquid biopsy” systems based on bio-
chips (36).
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